Edition:
India

TRACON Pharmaceuticals Inc (TCON.OQ)

TCON.OQ on NASDAQ Stock Exchange Global Market

2.95USD
15 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.95
Open
$2.95
Day's High
$3.03
Day's Low
$2.95
Volume
9,072
Avg. Vol
22,091
52-wk High
$6.20
52-wk Low
$2.00

Latest Key Developments (Source: Significant Developments)

Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Tracon Pharmaceuticals Inc ::Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget.Tracon Pharmaceuticals -‍in trial, 4 of 17 patients experienced partial response to treatment, eight additional patients (8/17, 47%) had stable disease​.Tracon Pharmaceuticals -‍in trial, combination of trc102,fludara produced evidence of tumor DNA damage that appeared to correlate with antitumor activity​.  Full Article

Tracon Pharma reports third quarter financial results
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Tracon Pharmaceuticals Inc :Tracon Pharmaceuticals reports third quarter financial results and provides corporate update.Tracon Pharmaceuticals Inc-qtrly ‍shr $0.07​.  Full Article

Tracon pharmaceuticals announces successful meetings with FDA, EMA for TRC105 in Angiosarcoma
Monday, 3 Oct 2016 

Tracon Pharmaceuticals Inc : Reached agreement with both regulatory agencies regarding key elements of phase 3 program for trc105 in angiosarcoma . Tracon pharmaceuticals announces successful meetings with fda and ema for trc105 (carotuximab) in angiosarcoma .Expects to initiate enrollment in phase 3 study by year-end.  Full Article

Tracon Pharma qtrly loss per share $0.68
Thursday, 11 Aug 2016 

Tracon Pharmaceuticals Inc : Tracon pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Tracon pharmaceuticals inc says collaboration revenue for q2 of 2016 was $0.8 million, compared to $4.2 million for q2 of 2015 . Qtrly loss per share $0.68 .Q2 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article

Tracon Pharmaceuticals announces positive results from TRC105 and TRC102 clinical trials
Monday, 6 Jun 2016 

Tracon Pharmaceuticals Inc : Reported positive results from three separate clinical trials evaluating two clinical stage product candidates, TRC105 and TRC102 . Median pfs greater than 12 months with continued durable complete responses observed in angiosarcoma patients treated with trc105 and votrient . Partial responses seen in solid tumor patients treated with trc102 and temodar . On track to initiate randomized phase 3 study of trc105 with votrient in patients with angiosarcoma later this year at sites in u.s., europe . Combination of trc105 and avastin was well-tolerated with no apparent increase in frequency or severity of adverse events . Data from randomized phase 2 trial comparing treatment with combination of trc105 and avastin expected by end of 2016 .Tracon pharmaceuticals announces positive results from trc105 and trc102 clinical trials at american society of clinical oncology (asco) 2016 annual meeting.  Full Article

Tracon Pharmaceuticals Q1 net loss $6.5 million
Thursday, 12 May 2016 

Tracon Pharmaceuticals Inc : Collaboration revenue for Q1 of 2016 was $1.2 million compared to $1.1 million for q1 of 2015 . Net loss for Q1 of 2016 was $6.5 million compared to a net loss of $4.0 million for Q1 of 2015 .Tracon Pharmaceuticals reports first quarter 2016 financial results and provides corporate update.  Full Article

TRACON Pharmaceuticals says Initiation of TRC102 Phase 2 Clinical Trial in Glioblastoma
Thursday, 28 Jan 2016 

TRACON Pharmaceuticals Inc:Says the initiation of a Phase 2 clinical trial, evaluating the combination of TRC102 and Temodar® (temozolomide) in patients with glioblastoma sponsored by the National Cancer Institute (NCI).  Full Article

BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara

* Tracon Pharmaceuticals announces positive results from phase 1 trial of trc102 and fludara® in patients with advanced hematologic malignancy published in oncotarget